Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment#United_States#Johnson_&_Johnson#Spring_House#nipocalimab#Systemic_Lupus
Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment
Nipocalimab, a novel treatment developed by Johnson & Johnson, has received Fast Track designation from the FDA for lupus therapy, addressing critical patient needs.
third-news.com
March 3, 2026 at 1:38 PM
Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment#United_States#Johnson_&_Johnson#Spring_House#nipocalimab#Systemic_Lupus
Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference#Canada#Toronto#Mallinckrodt#Acthar_Gel#Systemic_Lupus
Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference
Mallinckrodt highlights real-world data on Acthar Gel for systemic lupus erythematosus at LUPUS 2025, showcasing treatment effectiveness and patient profiles.
third-news.com
May 14, 2025 at 10:56 AM
Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference#Canada#Toronto#Mallinckrodt#Acthar_Gel#Systemic_Lupus